RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Filter Contribution Recycle: Boosting Model Pruning with Small Norm Filters

        Zehong Chen,Zhonghua Xie,Zhen Wang,Tao Xu,Zhengrui Zhang 한국인터넷정보학회 2022 KSII Transactions on Internet and Information Syst Vol.16 No.11

        Model pruning methods have attracted huge attention owing to the increasing demand of deploying models on low-resource devices recently. Most existing methods use the weight norm of filters to represent their importance, and discard the ones with small value directly to achieve the pruning target, which ignores the contribution of the small norm filters. This is not only results in filter contribution waste, but also gives comparable performance to training with the random initialized weights [1]. In this paper, we point out that the small norm filters can harm the performance of the pruned model greatly, if they are discarded directly. Therefore, we propose a novel filter contribution recycle (FCR) method for structured model pruning to resolve the fore-mentioned problem. FCR collects and reassembles contribution from the small norm filters to obtain a mixed contribution collector, and then assigns the reassembled contribution to other filters with higher probability to be preserved. To achieve the target FLOPs, FCR also adopts a weight decay strategy for the small norm filters. To explore the effectiveness of our approach, extensive experiments are conducted on ImageNet2012 and CIFAR-10 datasets, and superior results are reported when comparing with other methods under the same or even more FLOPs reduction. In addition, our method is flexible to be combined with other different pruning criterions.

      • KCI등재

        Effects of the friction coefficient on the torque characteristics of a hydraulic cam-rotor vane motor

        Qiankun Ma,Xuyong Wang,Fan Yuan,Liangshen Chen,Jianfeng Tao,Zhonghua Miao 대한기계학회 2016 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.30 No.8

        The friction coefficient between the vane and the slot is one of the most critical factors that affects the performance of a continuous rotary hydraulic cam-rotor vane motor. To study the effects of this coefficient on the torque characteristics of the motor, the mathematical model for the normal force and the disturbing torque between the cam rotors and the vanes of the motor was established by analyzing the forces exerted on the vanes. The mathematical model was simulated with MATLAB, and simulation results show that an increase in the friction coefficient would simultaneously decrease the normal force and increase the disturbing torque, which would negatively affect the performance of the motor. Further experimental research indicated that the low-speed performance of the hydraulic cam-rotor motor was significantly improved when the friction coefficient was reduced by controlling the parallelism tolerance, flatness and roughness between the vanes and the slots.

      • KCI등재

        Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis

        Ying Lin,Mingxi Lin,Jian Zhang,Biyun Wang,Zhonghua Tao,Yiqun Du,Sheng Zhang,Jun Cao,Leiping Wang,Xichun Hu 대한암학회 2020 Cancer Research and Treatment Vol.52 No.4

        Purpose Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. Materials and Methods One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included. Results Over half patients have received more than two lines of systematic therapy and exposed to two or more kinds of anti-HER2 agents. Most patients received a combined therapy, commonly of pyrotinib plus capecitabine, or vinorelbine or trastuzumab. Median progression-free survival (PFS) was 6.3 months (range, 5.54 to 7.06 months) and objective response rate (ORR) was 29.5%, with two patients (1.9%) achieving complete response. Lapatinib-naïve patients had significantly longer PFS than lapatinib-treated patients (9.0 months vs. 5.4 months, p=0.001). ORR for lapatinib-treated patients was 23.2%. Thirty-one of 113 patients have brain metastasis. Median PFS was 6.7 months and intracranial ORR was 28%. For patients without concurrent radiotherapy and/or brain surgery, the ORR was very low (6.3%). But for patients receiving concurrent radiotherapy and/or brain surgery, the ORR was 66.7%, and three patients achieved complete response. Most common adverse event was diarrhea. Conclusion Pyrotinib-based therapy demonstrated promising effects in metastatic HER2-positive BC and showed activity in lapatinib-treated patients. For patients with brain metastasis, pyrotinib-based regimen without radiotherapy showed limited efficacy, but when combined with radiotherapy it showed promising intracranial control.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼